Jeff Yass’s Phathom Pharmaceuticals PHAT Stock Holding History

Jeff Yass’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$220K	Sell	20,300 -21,000	-51%	-$240K	﹤0.01%	11741
2026 Q1	$459K	Buy	41,300 +22,400	+119%	+$283K	﹤0.01%	9899
2025 Q4	$314K	Sell	18,900 -1,000	-5%	-$14.3K	﹤0.01%	9838
2025 Q3	$234K	Sell	19,900 -384,700	-95%	-$3.97M	﹤0.01%	10645
2025 Q2	$3.88M	Buy	404,600 +385,800	+2,052%	+$2.13M	﹤0.01%	4456
2025 Q1	$118K	Sell	18,800 -238,600	-93%	-$1.45M	﹤0.01%	11425
2024 Q4	$2.09M	Buy	257,400 +239,100	+1,307%	+$2.96M	﹤0.01%	5222
2024 Q3	$331K	Sell	18,300 -11,900	-39%	-$166K	﹤0.01%	9383
2024 Q2	$311K	Sell	30,200 -19,500	-39%	-$201K	﹤0.01%	9360
2024 Q1	$528K	Buy	+49,700	New	+$422K	﹤0.01%	8374
2023 Q4	–	Sell	-26,200	Closed	-$272K	–	13071
2023 Q3	$272K	Sell	26,200 -7,800	-23%	-$107K	﹤0.01%	9571
2023 Q2	$487K	Buy	+34,000	New	+$392K	﹤0.01%	8386
2021 Q1	–	Sell	-14,700	Closed	-$488K	–	12691
2020 Q4	$488K	Buy	+14,700	New	+$596K	﹤0.01%	8345

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Jeff Yass's PHAT Position: Q2 2026 in Review

Jeff Yass reduced its Phathom Pharmaceuticals (PHAT) stake by 81% in Q2 2026, selling an estimated $859K and leaving 17,725 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #11993.

Jeff Yass first reported a position in PHAT in Q4 2020 and has held it in 16 quarters since. The position peaked at $9.11M in Q4 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

Jeff Yass held 17,725 shares of Phathom Pharmaceuticals worth $192K as of Q2 2026.
Jeff Yass sold 75,254 Phathom Pharmaceuticals shares in Q2 2026, an estimated $859K.
Phathom Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11993 holding.
Jeff Yass first reported a position in Phathom Pharmaceuticals in Q4 2020 and has held it in 16 quarters since.
Jeff Yass's Phathom Pharmaceuticals position peaked at $9.11M in Q4 2025.
161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.